Revolution Medicines unveiled additional early data for daraxonrasib, its RAS-pathway targeted therapy, including tumor control signals when dosed early in first-line pancreatic cancer and in combination settings. Results presented at the American Association for Cancer Research meeting pointed to meaningful response rates and a six-month snapshot of progression-free status in RAS-mutated patients. In parallel, reporting highlighted the company’s broader daraxonrasib development plan across solid tumor settings, with analysts watching the expansion of the drug’s apparent activity beyond a narrow mutation definition. Separately, additional discussion at AACR focused on daraxonrasib’s longer-term positioning and the company’s work on follow-on RAS-programs. The updates come as the FDA provided Revolution with a regulatory fast-track pathway for daraxonrasib, which could shorten timelines from submission to review depending on the final evidence package.